Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate

BACKGROUND: Gemcitabine (GEM) is one of the first-line chemotherapies for bladder cancer (BC), but the GEMs cannot recognize cancer cells and have a low long-term response rate and high recurrence rate with side effects during the treatment of BC. Targeted transport of GEMs to mediate cytotoxicity t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Wei, Peng, Yongbo, Zeng, Hongliang, Yu, Chunping, Zhang, Qun, Liu, Biao, Liu, Jiahao, Hu, Xing, Wei, Wensu, Deng, Minhua, Wang, Ning, Liu, Xuewen, Xie, Jianfei, Hou, Weibin, Tang, Jin, Long, Zhi, Wang, Long, Liu, Jianye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721011/
https://www.ncbi.nlm.nih.gov/pubmed/36471380
http://dx.doi.org/10.1186/s40824-022-00328-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721011/
https://www.ncbi.nlm.nih.gov/pubmed/36471380
http://dx.doi.org/10.1186/s40824-022-00328-9

Ejemplares similares